Evidence map›Paper›PMID 35242065›Full record

ArticleFrontiers in psychiatry2022

A Case Report of Excessive Use of Clozapine Combined With Clonazepam.

Wei Li, Yan Liu, Haifeng Jiang, Jiang Du, Yan Zhao, Zheyi Du, Shuo Li, Haihong Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wei LiShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Yan LiuShanghai Baoshan Mental Health Center, Shanghai, China.
Haifeng JiangShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Jiang DuShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Yan ZhaoShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Zheyi DuShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shuo LiShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Haihong WangShanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shanghai Mental Health Center · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFor patients with schizophrenia, clozapine (CLZ) in combination with clonazepam (CLNAZ) is one of the viable therapeutic options. We successfully reduced the doses of CLZ and CLNAZ to the safe range of a polydrug abuse patient. As far as we know, this is the first case of this problem. As there are no relevant guidelines to reduce CLZ or CLNAZ, we hope to share this case to provide a reference for the prevention and treatment of similar patients with multidrug abuse. CASE PRESENTATION: This case report describes a 46-year-old male with a 24-year history of schizophrenia. His main clinical manifestations are auditory hallucinations, persecutory delusion, and emotional instability. In 2012, the patient started taking rifampicin due to tuberculosis and gradually overused CLZ and CLNAZ. Before admission, he took 1,275 mg of CLZ every day and 26 mg of CLNAZ every night. With the help of Therapeutic Drug Monitoring (TDM) and pharmacogenetic testing, we gradually reduced his daily dose of CLZ and CLNAZ and formulated a more reasonable dosing schedule for him. At the time of discharge, the patient took CLZ 450 mg per day and CLNAZ 2 mg per night, with no obvious symptoms of psychosis.

conclusionIn the process of drug maintenance treatment of schizophrenia, it is necessary to adopt TDM strategy to reduce and treat the abuse of multiple prescription drugs.

Indexed as

case reportclonazepamclozapineschizophreniatherapeutic drug monitoring (TDM)withdrawal

Identifiers

PMID35242065
PMCPMC8885542
OpenAlexW4212928883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.